03:36 , Jan 4, 2019 |  BC Innovations  |  Tools & Techniques

Making AD mice as diverse as patients

The Jackson Laboratory aims to make Alzheimer’s disease mouse models more useful for predicting which patients will respond to therapy by engineering in a high degree of genetic diversity to better reflect trial populations. The...
07:01 , Dec 18, 2018 |  BC Extra  |  Tools & Techniques

Gritstone showcases mass spec-based neoantigen discovery platform

Gritstone Oncology Inc. (NASDAQ:GRTS) unveiled the inner workings of its mass spectrometry-based neoantigen identification platform, EDGE, in a Nature Biotechnology study published Monday. Results from the paper suggest building a machine-learning algorithm based on human...
14:42 , Dec 11, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Amyotrophic lateral sclerosis (ALS) Cell culture studies identified a pyridocarbazole-based inhibitor of disease-associated hairpin forms of GGGGCC repeat expansions in C9orf72 that could help treat ALS. In HEK cells, an optimized version of a...
03:31 , Dec 7, 2018 |  BC Innovations  |  Tools & Techniques

Germline editing gets technical

As the smoke clears from Jiankui He’s bombshell germline editing announcement, the gap between where the gene editing field is now and where it would need to be to support responsible germline editing has become...
22:02 , Dec 6, 2018 |  BC Week In Review  |  Clinical News

Stoke unveils Dravet data that supported $90M series B

Stoke Therapeutics Inc. (Bedford, Mass.) presented the preclinical data for its Dravet syndrome antisense oligonucleotide (ASO) therapy that CEO Ed Kaye said helped it raise its $90 million series B round in October. In a...
14:49 , Dec 4, 2018 |  BC Extra  |  Preclinical News

Stoke unveils Dravet data that supported $90M series B

Stoke Therapeutics Inc. (Bedford, Mass.) presented the preclinical data for its Dravet syndrome antisense oligonucleotide (ASO) therapy that CEO Ed Kaye said helped it raise its $90 million series B round in October. In a...
13:08 , Dec 4, 2018 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: Gene profiling; tissue markers Analysis of the copy numbers of mutant and wild-type alleles of oncogenes could help predict response to cancer therapies targeting those oncogenes. The method involves: performing genome-wide, allele-specific copy number...
16:43 , Sep 21, 2018 |  BC Week In Review  |  Clinical News

Eureka's ET140202 leads to tumor regression in Phase I for HCC

Eureka Therapeutics Inc. (Emeryville, Calif.) said ET140202 led to one case of complete tumor regression and two cases of partial tumor regression in six evaluable patients with alpha fetoprotein (AFP)-positive hepatocellular carcinoma (HCC) in a...
23:35 , Aug 22, 2018 |  BC Innovations  |  Translation in Brief

Confirming CRISPR

Two critiques of a 2017 human embryo gene editing study, including one suggesting large deletions at the target site misled researchers into thinking CRISPR-Cas9 corrected a genetic mutation, raise questions about what assays and screening...
21:30 , Jul 24, 2018 |  BC Innovations  |  Translation in Brief

Interaction analysis

In a collaboration with Merck & Co. Inc. (NYSE:MRK) and SomaLogic Inc., University of Cambridge researchers have identified associations and causal relationships between thousands of genetic variants, plasma proteins and disease states, which could reveal...